| [August 01, 2011] |
 |
Research and Markets: Age Related Macular Degeneration Pipeline Review, Q2 2011 - A Comprehensive Snapshot of the Global Therapeutic Scenario for Age Related Macular Degeneration
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/69a969/age_related_macula)
has announced the addition of Global Markets Direct's new report "Age
Related Macular Degeneration - Pipeline Review, Q2 2011" to their
offering.
Global Markets Direct's, 'Age
Related Macular Degeneration - Pipeline Review, Q2 2011', provides
an overview of the Age Related Macular Degeneration therapeutic
pipeline. This report provides information on the therapeutic
development for Age Related Macular Degeneration, complete with latest
updates, and special features on late-stage and discontinued projects.
It also reviews key players involved in the therapeutic developmentfor
Age Related Macular Degeneration.
'Age
Related Macular Degeneration - Pipeline Review, Q2 2011' is built
using data and information sourced from Global Markets Direct's
proprietary databases, Company/University websites, SEC (News - Alert) filings,
investor presentations and featured press releases from
company/university sites and industry-specific third party sources, put
together by Global Markets Direct's team.
Note: Certain sections in the report may be removed or altered based on
the availability and relevance of data for the indicated disease.
Scope:
-
A snapshot of the global therapeutic scenario for Age Related Macular
Degeneration.
-
A review of the Age Related Macular Degeneration products under
development by companies and universities/research institutes based on
information derived from company and industry-specific sources.
-
Coverage of products based on various stages of development ranging
from discovery till registration stages.
-
A feature on pipeline projects on the basis of monotherapy and
combined therapeutics.
-
Coverage of the Age Related Macular Degeneration pipeline on the basis
of therapeutic class, route of administration and molecule type.
-
Profiles of late-stage pipeline products featuring sections on product
description, mechanism of action and research & development progress.
Reasons to Buy:
-
Identify and understand important and diverse types of therapeutics
under development for Age Related Macular Degeneration.
-
Identify emerging players with potentially strong product portfolio
and design effective counter-strategies to gain competitive advantage.
-
Plan mergers and acquisitions effectively by identifying players with
the most promising pipeline.
-
Devise corrective measures for pipeline projects by understanding Age
Related Macular Degeneration pipeline depth and focus of Age Related
Macular Degeneration therapeutics.
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
-
Modify the therapeutic portfolio by identifying discontinued projects
and understanding the factors that drove them from pipeline.
For more information visit http://www.researchandmarkets.com/research/69a969/age_related_macula
[ Back To TMCnet.com's Homepage ]
|
